Last update: Jan. 29, 2017

Tranexamic Acid

Very Low Risk for breastfeeding

Safe. Compatible.
Minimal risk for breastfeeding and infant.

Anti-fibrinolytic drug that is used on the treatment and prophylaxis of hereditary angioedema, menorrhagia and other hemorrhagic disorders.

It is excreted into breast milk in a non-significant amount: the concentration measured in the milk was 1% of plasma concentration (Verstraeten 1985, WHO 2010, Caballero 2012).
Despite of that low observed concentration, an expert consensus did not recommend its use while breastfeeding (Caballero 2012).

No clinical or developmental issues have been observed in the short and long term among 21 infants whose mothers were treated with it. (Gilad 2014).

Scientific societies and some consensus of experts believe it is compatible the use of Tranexamic acid during breastfeeding (WHO 2010, Bouillet 2015).


We do not have alternatives for Tranexamic Acid since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Tranexamic Acid is also known as

Tranexamic Acid in other languages or writings:


Tranexamic Acid belongs to this group or family:


Main tradenames from several countries containing Tranexamic Acid in its composition:


Variable Value Unit
Oral Bioavail. 30 - 50 %
Molecular weight 157 daltons
Protein Binding 3 %
Tmax 3 hours
T1/2 2 hours
M/P ratio 0,01 -


  1. Bouillet L, Lehmann A, Gompel A, Boccon-Gibod I, Launay D, Fain O; CREAK.. [Hereditary angiœdema treatments: Recommendations from the French national center for angiœdema (Bordeaux consensus 2014)]. Presse Med. 2015 Abstract
  2. Gilad O, Merlob P, Stahl B, Klinger G. Outcome following tranexamic acid exposure during breastfeeding. Breastfeed Med. 2014 Abstract
  3. Caballero T, Farkas H, Bouillet L, Bowen T, Gompel A, Fagerberg C, Bjökander J, Bork K, Bygum A, Cicardi M, de Carolis C, Frank M, Gooi JH, Longhurst H, Martínez-Saguer I, Nielsen EW, Obtulowitz K, Perricone R, Prior N; C-1-INH Deficiency Working Group.. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012 Abstract Full text (link to original source) Full text (in our servers)
  4. Pfizer. Tranexamic acid (Cyklokapron). Drug Summary. 2011 Full text (in our servers)
  5. Shakur H, Elbourne D, Gülmezoglu M, Alfirevic Z, Ronsmans C, Allen E, Roberts I. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials. 2010 Abstract
  6. AEMPS. Ácido Tranexámico (Amchafibrin) Ficha técnica. 2010 Full text (in our servers)
  7. WHO. 18th Expert Committee on the Selection and Use of Essential Medicines. Tranexamic acid. WHO EML. 2010 Full text (link to original source) Full text (in our servers)
  8. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs. 1985 Abstract
  9. Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol. 1981 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by El Parto Es Nuestro from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM